X-Chem, a leading provider of early-stage drug discovery solutions, has appointed Dr. Erin Davis as its chief technology officer. Dr. Davis brings extensive experience in data strategy, informatics, computational chemistry, and software solutions for drug discovery to the company’s executive team. Her addition to X-Chem strengthens the company’s focus on utilizing data generation platforms and digital drug discovery solutions for clients.
With expertise in DNA-encoded library technology, discovery and synthetic chemistry, and machine learning through its ArtemisAI platform, X-Chem is well-positioned to combine real-world data generation and advanced machine learning for accelerated drug discovery. Dr. Davis’ unique background in integrating computational platforms with robust data strategies will play a key role in X-Chem’s growth as a leader in innovative services for small molecule drug discovery.
X-Chem specializes in small molecule discovery, offering pharmaceutical and biotech companies a comprehensive solution for screening, hit validation, and lead optimization. Through its DNA-encoded chemical library (DEL) technology and ArtemisAI platform, X-Chem discovers novel small molecule leads for challenging therapeutic targets. The company’s expertise in medicinal chemistry, custom synthesis, and scale-up process chemistry supports all aspects of small-molecule drug discovery, from identification to development.
Karen Lackey, X-Chem’s CEO, expressed excitement about Dr. Davis joining the team, highlighting her creativity and innovation in a company known for cutting-edge technology. Lackey believes that Dr. Davis and the team at X-Chem will revolutionize the way small molecule drugs are discovered by combining real-world data generation with advanced machine learning techniques.
In conclusion, the appointment of Dr. Erin Davis as chief technology officer at X-Chem is an exciting development that strengthens the company’s focus on utilizing data generation platforms and digital drug discovery solutions for clients. With its expertise in small molecule discovery and advanced machine learning techniques like ArtemisAI platform
